Abstract
In this case report, we present the first report of erythema elevatum diutinum after treatment of juvenile idiopathic arthritis with abatacept. Although it could also be coincidental, in our case, the appearance of vasculitis was not blocked by the simultaneous administration of a stimulation inhibitor, and alerts to the fact that as effective as a abatacept may be to control of the inflammatory articular symptoms, this might not translate into control of the disease.
MeSH terms
-
Abatacept
-
Administration, Topical
-
Adolescent
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Juvenile / complications
-
Arthritis, Juvenile / drug therapy*
-
Erythema / drug therapy
-
Erythema / etiology*
-
Erythema / pathology
-
Female
-
Glucocorticoids / therapeutic use
-
Humans
-
Immunoconjugates / adverse effects*
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Vasculitis, Leukocytoclastic, Cutaneous / drug therapy
-
Vasculitis, Leukocytoclastic, Cutaneous / etiology*
-
Vasculitis, Leukocytoclastic, Cutaneous / pathology
Substances
-
Antirheumatic Agents
-
Glucocorticoids
-
Immunoconjugates
-
Tumor Necrosis Factor-alpha
-
Abatacept